KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Asset Writedowns and Impairment (2023 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Asset Writedowns and Impairment for 3 consecutive years, with -$1.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Asset Writedowns and Impairment fell 117.78% to -$1.2 million in Q4 2025 year-over-year; TTM through Sep 2025 was $8.1 million, a 63.34% decrease, with the full-year FY2024 number at $8.9 million, up 11.25% from a year prior.
  • Asset Writedowns and Impairment was -$1.2 million for Q4 2025 at Supernus Pharmaceuticals, down from -$239000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $20.2 million in Q4 2023 to a low of -$1.2 million in Q4 2025.
  • A 3-year average of $3.2 million and a median of $730000.0 in 2024 define the central range for Asset Writedowns and Impairment.
  • Biggest YoY gain for Asset Writedowns and Impairment was 25.07% in 2025; the steepest drop was 724.14% in 2025.
  • Supernus Pharmaceuticals' Asset Writedowns and Impairment stood at $20.2 million in 2023, then plummeted by 65.81% to $6.9 million in 2024, then tumbled by 117.78% to -$1.2 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Asset Writedowns and Impairment are -$1.2 million (Q4 2025), -$239000.0 (Q3 2025), and $920000.0 (Q2 2025).